When drug prices are too high for patients, physicians take on additional workload to find solutions. A newly released 2026 ...

Pelago launched a behavioral health platform that integrates substance use, mental health and behavioral addiction care, ...

A growing group of companies is developing new immunology drugs to challenge Dupixent, the blockbuster Sanofi product with a dominating presence in multiple inflammatory indications. North Immunology ...

Eli Lilly’s partnership with InnoCare Pharma follows deals struck this year with other China-based companies. While ...

CertifyOS launched a shared credentialing program that allows providers to submit their information once for multiple health ...

The question is whether these AI tools will be another fragmented layer of technology or true assistants to help them spend ...

ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran is in Phase 3 testing for the rare disease hereditary ...

Healthcare leaders know how to test software. We don't yet have a shared playbook for onboarding agents expected to do a job ...

The Centers for Medicare & Medicaid Services (CMS) took constructive steps in its 2027 final rule and rate announcement, particularly on payment integrity and quality measurement. But those steps are ...

They see the problem first, build the fix, and decide whether it is ever adopted. The market has trained them to hide the one credential that de-risks the deal.

We have spent years making the chart more accessible to patients. OpenNotes helped establish that patients should be able to read what their doctors write about them, and federal information-blocking ...

Amgen’s dazodalibep led to statistically significant and clinically meaningful results, according to preliminary Phase 3 ...